Published · Last updated:
This guide reflects FDA, FTC, Google and Meta pages read on October 20, 2026, and is scheduled for review by January 31, 2027, because FDA enforcement on compounded GLP-1 marketing moves quickly. It is general marketing information for US med spas, not medical or legal advice.
Marketing a Medical Weight Loss Program at a Med Spa: GLP-1 Claims, Compounded Drug Wording and a Program Page That Books Consults
Med spa weight loss marketing in 2026 starts with drug wording: a program page can describe GLP-1 treatment, but it cannot imply that a compounded drug is the same as, or a generic of, an FDA-approved one. On March 3, 2026, FDA announced 30 warning letters to telehealth companies over compounded GLP-1 marketing, and claims implying sameness with FDA-approved products led its list of primary violations. [1]
- FDA announced 30 warning letters to telehealth companies on March 3, 2026. Primary violations included claims implying sameness with FDA-approved products and compounded drugs branded with the seller's own name or trademark without qualification. [1]
- Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness or quality before they are marketed. FDA also states that they are not the same as generic drugs. [1] [2]
- A result is a health claim. The FTC expects health benefit claims to rest on competent and reliable scientific evidence, generally randomized, controlled human clinical testing, and an honest testimonial is not that evidence. [3]
- The program page this guide adds answers six questions in order: who the program is for, who prescribes, how screening works, where the medication comes from, what the price includes and how to book a consult.
- Most Ambrose clients invest roughly $1,200 to $4,000 a month in marketing, often across more than one channel. Book a free consultation and we will read your program page against the FDA and FTC themes in this guide.
The pages that rank for this question today are a state-specific law firm post, a booking software guide and a trade news article. None of the three, read for this guide on October 20, 2026, cites FDA's March 2026 warning letters, and none turns the rules into page copy. This guide does both. It reads the FDA, FTC, Google and Meta pages as written, with the date each was read, and turns them into wording rules and a program page built to book consults. Our med spa marketing agency builds these pages for practices that add a medical weight loss program.
The pace of enforcement is the reason to start now. FDA says that over the six months before March 3, 2026, it sent thousands of letters warning pharmaceutical and telehealth firms to remove misleading ads, more than it had sent over the entire preceding decade. [1] The 30 letters went to telehealth companies, not med spas. The two themes FDA named, though, describe sentences any program page can contain.
What FDA Flagged in 2026: Sameness Claims and Own-Name Branding of Compounded GLP-1 Drugs
FDA's March 3, 2026 announcement named two primary violations across 30 warning letters to telehealth companies. The first was making claims implying sameness with FDA-approved products. The second was advertising compounded drugs branded with the telehealth firm's own name or trademark without qualification, which implies the firm is the compounder. [1] Both are sentences on a web page, so a med spa can fix both before they ship.
A compounded drug is one a compounder prepares outside FDA's approval process. FDA states the status plainly: compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness or quality before they are marketed. [2] The March announcement adds one more line that matters for page copy: "Compounded drugs are also not the same as generic drugs, which are FDA-approved." [1] That sentence rules out the most common shortcut on weight loss pages, which is calling a compounded product a generic of a brand-name drug.
FDA does not treat compounding itself as the problem. In the same announcement, FDA Commissioner Marty Makary, M.D., M.P.H., said compounded drugs can be important for overcoming shortages or meeting unique patient needs. [1] FDA's GLP-1 page says a compounded drug might be appropriate when a patient's medical need cannot be met by an FDA-approved drug, or when the FDA-approved drug is not commercially available. [2] The violation FDA named is marketing that blurs the line between the two.
FDA's GLP-1 page also carries a sourcing warning that belongs in your vendor file. Some compounded semaglutide products may use salt forms such as semaglutide sodium or semaglutide acetate. FDA calls these different active ingredients than the ones used in the approved drugs and says it is not aware of any lawful basis for their use in compounding. [2] Ask your compounding pharmacy in writing which form it uses before your program page names the medication.
FDA also counts safety reports. As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA notes that adverse events from compounded versions are likely underreported. [2] These are reports, not proven causes. A program page should not use them as marketing in either direction.
Words to Use and Avoid on a Weight Loss Program Page
A weight loss program page that offers compounded GLP-1 medication should avoid four kinds of wording: sameness or generic claims, the label FDA approved, the spa's own brand name on the drug without qualification, and outcome promises. FDA's pages are the source for the first three, and the FTC's health guidance is the source for the fourth. [1] [2] [3] Describe the medication, its source and its prescriber instead.
The table pairs each risky phrase with the source line behind it and a safer framing. The right-hand column is a starting draft for your medical director and healthcare counsel, not cleared copy.
| Avoid | Why | Safer framing to confirm with counsel |
|---|---|---|
| "Generic Ozempic" or "generic semaglutide" for a compounded product | FDA: compounded drugs are not the same as generic drugs, which are FDA-approved [1] | Compounded semaglutide, prepared by a named state-licensed pharmacy |
| "Same as," "identical to" or "the same medication as" a brand-name drug | Sameness claims were a primary violation in the 30 letters, and FDA lists a same-as-approved claim as a consumer red flag [1] [2] | A compounded medication; compounded drugs are not FDA approved |
| Calling a compounded product FDA approved | Compounded drugs are not FDA approved, and FDA does not review them before they are marketed [2] | Compounded medications are not FDA approved or reviewed by FDA for safety, effectiveness or quality |
| Your spa's name or program trademark on the drug itself | A compounded drug branded with the seller's name without qualification implies the seller is the compounder [1] | Brand the program, not the drug; name the compounding pharmacy beside the medication |
| A number of pounds in a number of weeks, or guaranteed results | FTC: health claims generally need randomized, controlled human clinical testing; Meta bars promised outcomes within a set timeframe without qualifiers [3] [7] | Describe the program's steps, visits and medical oversight, with no outcome numbers |
| "No doctor visit needed" or instant prescriptions | FDA lists a seller that does not require screening and a prescription by a licensed doctor as a red flag [2] | Every patient is screened by a licensed prescriber before any medication is prescribed |
FDA's GLP-1 page also publishes a list of telehealth red flags for consumers. Read by a marketer, it is an audit list. A seller that claims a compounded drug is the same as an FDA-approved one, offers medicine at deep discounts or prices that seem too good to be true, or does not require a screening and prescription by a licensed doctor matches the patterns FDA tells patients to avoid. [2] A program page that passes that list is easier for a careful patient to trust.
The test for every sentence is short. If a sentence would be false about a compounded product, it does not belong on a page that sells one.
Program Page Claim Check
This checker does not review your page, estimate cost or predict any result, and it is not legal or medical advice. It restates the wording table in this guide. Sources: FDA (announcement of March 3, 2026; GLP-1 page current as of October 1, 2026), FTC Health Products Compliance Guidance (December 2022) and Meta health and wellness ad standards, all read October 20, 2026.
Pick the phrase closest to one on your current page. The checker shows the theme behind it, the source, a safer framing to take to counsel and who signs off. It restates the wording table above and does not review your page.
Adding a GLP-1 program and unsure what your page can say? Book a 15-minute consult and we will read your program page against the FDA and FTC themes in this guide.
Book Your Free Consultation →Results, Before-and-After Photos and Testimonials Need Evidence, Not Just Patient Consent
A weight loss result on a program page is a health claim, whether it appears as a headline, a testimonial or a before-and-after photo. The FTC's Health Products Compliance Guidance, dated December 2022, says that as a general matter "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing". [3] A patient's consent to share a photo does not supply that evidence.
The FTC is direct about testimonials. Its guidance says an honest opinion or experience from an endorser is not enough on its own, and that testimonials reporting results more dramatic than users can generally expect are likely to be deceptive. [3] A fine-print "Results not typical" line does not cure that deception, according to the same guidance. [3]
The FTC even works through a weight loss case. In its example, a supplement ad shows a woman's before-and-after photographs and quotes her accurate account of her own loss, with a fine-print disclaimer that the results are not typical. A controlled trial of the product showed a much smaller average loss, so the FTC treats the vague disclaimer as inadequate and says a prominent statement of the study's average result, placed next to the quote, is likely to be effective. [3]
Reviews carry a separate federal rule. The FTC's final rule, announced August 14, 2024, bans fake reviews and testimonials, including ones that misrepresent that they are by someone who does not exist or who did not have actual experience with the business. It bars buying them, and it bars rewards conditioned on a review expressing a particular sentiment. The FTC can seek civil penalties against knowing violators. [4]
Meta adds platform limits to the same material. Its health and wellness ad standards bar weight loss ads that contain statements of inferiority about physical appearance or that close up on a specific body area by pinching fat. [7]
- Leave outcome numbers off the program page unless your medical director can point to the evidence behind them. [3]
- If counsel approves a testimonial, place a clear statement of what a typical patient can expect beside it, as the FTC guidance describes. [3]
- Ask every patient for an honest review, with no reward tied to a positive one. [4]
- Get each patient's written authorization before a photo or story is used, on a form your counsel approves.
Ads Run on a Separate Rulebook From the Program Page
A weight loss program page answers to FDA, the FTC and your state. A weight loss ad also answers to each platform's policy, which decides whether the ad runs at all. On Meta, a prescription drug advertiser such as a telehealth provider must be actively certified with LegitScript, obtain Meta's authorization and target only people 18 or older in eligible countries, which include the United States. [6]
Meta's prescription drug ads must also include a disclaimer to consult a licensed health professional or obtain a valid prescription. [6] Meta does not require written authorization for ads that promote telehealth services generally, and its health and wellness standards send weight loss products that require a prescription to the Drugs and Pharmaceuticals policy. [6] [7] Which policy an ad falls under depends on what it promotes, so confirm the classification with Meta before launch.
Every Meta ad for weight loss products and services must target people 18 or older. Meta also bars clickbait in a weight loss context, including promises of specific outcomes within a set timeframe without disclaimers or qualifiers. [7]
On Google, the Healthcare and medicines policy says advertisers must apply to serve ads for prescription drug services, and that in the United States Google allows telemedicine providers accredited by LegitScript's Healthcare Merchant Certification Program. [5] How Google treats drug names such as semaglutide in ad copy and keywords is covered line by line in our med spa Google Ads rules guide, so this guide does not restate it.
The Program Page That Books Consults: Six Sections in Order
A weight loss program page that books consults answers six questions in order: who the program is for, who prescribes, how screening works, where the medication comes from, what the price includes and how to book. Each answer also works as a compliance control. It replaces a sentence that FDA or the FTC has objected to with a fact a patient can check. [1] [3]
Who the program is for
Describe the patients your medical director treats, and say that eligibility is the prescriber's decision after screening. FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. [2]
Who prescribes
Name the licensed prescriber and the medical director, with credentials, and say whether visits are in person or by telehealth. FDA tells patients to be wary of a seller with no licensed doctor available to answer questions after the medication arrives. [2]
How screening works
List the steps before any prescription: the intake, the consult and anything else your medical director requires. FDA flags sellers that do not require a screening and prescription by a licensed doctor. [2]
Where the medication comes from
Say whether the program uses an FDA-approved brand-name drug, a compounded drug or both. For compounded medication, name the state-licensed pharmacy and state that compounded drugs are not FDA approved. [1] [2]
What the price includes
If you show a program price, say what it covers: visits, follow-ups and whether medication is included. CMS states that a provider must give a good faith estimate to a patient who is not using health insurance; ask counsel how that applies to your program fees. [8]
How to book
Give the page one action: book a consult. Avoid checkout language that suggests a patient can buy medication before a prescriber has seen them.
The CMS timing rules shape the booking path. When care is scheduled 3 to 9 business days ahead, the estimate is due within 1 business day; when it is scheduled 10 or more business days ahead, or the patient asks before scheduling, it is due within 3 business days. [8] Build that step into the consult confirmation, not the marketing page.
The six sections also give the page what a careful patient looks for first: a named prescriber, a named pharmacy and a clear next step. If your current site cannot carry them on one page, our website design and development team builds program pages on this structure, and our med spa SEO guide covers how treatment pages earn visibility in Google and AI answers.
Frequently Asked Questions About Med Spa Weight Loss Marketing
Can a med spa advertise semaglutide?
Can I call a compounded GLP-1 "generic Ozempic"?
Can a med spa post weight loss before-and-after photos?
Does FDA allow compounded semaglutide at all?
Who should approve the claims on a weight loss program page?
References
- U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. 2026-03-03; read 2026-10-20. fda.gov
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. content current as of 2026-10-01; read 2026-10-20. fda.gov
- Federal Trade Commission. Health Products Compliance Guidance. December 2022; read 2026-10-20. ftc.gov
- Federal Trade Commission. Federal Trade Commission Announces Final Rule Banning Fake Reviews and Testimonials. 2024-08-14; read 2026-10-20. ftc.gov
- Google Ads Policy Help. Healthcare and medicines (176031). no page date; read 2026-10-20. support.google.com
- Meta Transparency Center. Drugs and Pharmaceuticals ad standards. latest change log entry 2025-02-26; read 2026-10-20. transparency.meta.com
- Meta Transparency Center. Health and Wellness ad standards. latest change log entry 2026-07-23; read 2026-10-20. transparency.meta.com
- Centers for Medicare and Medicaid Services. Good faith estimate. page last modified 2026-10-05; read 2026-10-20. cms.gov
A Weight Loss Program Page That Books Consults Describes the Program, Not the Drug's Reputation
Med spa weight loss marketing that holds up in 2026 says less about the drug and more about the program. FDA's March 2026 letters named sameness claims and own-name branding of compounded GLP-1 drugs, and FDA states that compounded drugs are not FDA approved. [1] [2] The FTC asks for clinical evidence behind any result you show. [3]
Write the six sections, run every phrase through the wording table and have your medical director and counsel sign off before launch. Then measure booked consults, not clicks. What a launch costs across channels is covered in our med spa marketing cost guide; this guide covers what the program page may say.
Ready to build a weight loss program page that books consults?
We will read your program page and ads against the FDA, FTC and platform rules in this guide and show which sentences to change. You can also explore our med spa marketing, website design and development and paid advertising services, or hire Ambrose directly.
Book Your Free Consultation →This article is general marketing information as of its last-updated date, not medical or legal advice. It makes no claim about weight loss outcomes for any patient or medication. Confirm program wording with healthcare counsel, your medical director and your state pharmacy board before publishing, and confirm current rules on each platform's policy page.